



Gilenya[®] (fingolimod): Pregnancy-Specific Patient Reminder Card



Before starting Gilenya® treatment



Gilenya® can harm an unborn baby. Before you start treatment with Gilenya®, your doctor will inform you about the risks to the unborn baby and explain what you should do to avoid becoming pregnant while you are taking Gilenya®.



Your doctor will ask you to take a pregnancy test to ensure that you are not pregnant before you start treatment with Gilenya®.



Your doctor will inform you about the need for effective contraception while on treatment and for 2 months after discontinuation. Talk to your doctor about the most effective contraception options available to you.

Please read the Gilenya® Patients, Parents and Caregivers Guide provided by your doctor.

While you are taking Gilenya®



You should not become pregnant while taking Gilenya® and for 2 months after stopping treatment.

You should use effective contraception during treatment and for 2 months after discontinuing treatment to avoid becoming pregnant.

Your doctor will ask you to repeat pregnancy tests at suitable intervals.

Your doctor will provide regular counselling about Gilenya®'s serious risks to the unborn baby.



Tell your doctor straight away if you become pregnant or if you want to become pregnant because your doctor will consider stopping your Gilenya® treatment.

While you are taking Gilenya®



In the event of a pregnancy your doctor will provide counselling. Your doctor will give you medical advice regarding the harmful effects of Gilenya® to the fetus and will perform medical follow-up examination. An ultrasonography examination should be performed, and Gilenya® treatment will be discontinued.



Your doctor may inform Novartis about your pregnancy so as to monitor the outcomes of pregnancy in women exposed to Gilenya® during pregnancy.

After stopping Gilenya[®] treatment



Inform your doctor immediately if you believe your MS is getting worse (e.g. weakness or visual changes) or if you notice any new symptoms after stopping treatment with Gilenya[®] due to pregnancy.



Effective contraception is needed for 2 months after stopping Gilenya[®] treatment because of the length of time it takes for Gilenya[®] to leave the body.



HSA Approved RMP - Gilenya Patient Pregnancy Guide

This material is also available online.

Please scan this QR code

or visit <https://www.medhub.novartis.com.sg/ermp/gilenya>

Gilenya® is a registered trademark of Novartis Pharma AG



Novartis (Singapore) Pte Ltd

20 Pasir Panjang Road,
#10-25/28 Mapletree Business City,
Singapore 117439
Phone: +65 6722 6010 • Fax: +65 6323 4335 • www.novartis.com

This document has been approved by HSA on 10 Jun 2021.

Version 18.0 | Printed Jul 2024

FA-11236897 | Date of approval: 25th Jul 2024